首页> 外文期刊>Seminars in cancer biology >Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact.
【24h】

Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact.

机译:原发性和转移性病变的免疫细胞浸润:机制和临床影响。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The infiltration of tumors and their metastases by hematopoietic cells can contribute both positively and negatively to tumor growth, invasion, and patient outcomes. These differing outcomes are associated with both tumor heterogeneity and the diversity of leukocytes infiltrating neoplastic lesions. Tumors infiltration by histiocytes (macrophages and dendritic cells (DCs)) is associated with poor clinical outcomes, although infiltration by a subset of DCs is related to improved outcomes. T-cell infiltration of tumors and metastases are surrogates for positive outcomes, although subset analysis suggests that not all infiltrating T-cells have this potential. Overall, tumor infiltration by CD8(+) T-cells is associated with a positive outcome, while the frequency of infiltrating CD4(+) cells may be a negative predictor. In addition to tumor infiltration by macrophages and T-cells, recent studies have shown that myeloid-derived suppressor cells (MDSCs), also infiltrate tumors, inhibiting T-cell and DC number and function and facilitate tumor growth, angiogenesis, and metastasis. In summary, hematopoietic cell infiltration of tumors can regulate tumor progression and provide a useful diagnostic surrogate. Further, strategies focused on the manipulation of cellular infiltration via cellular, gene and molecular immunotherapies have the potential to provide a novel target for adjuvant therapy.
机译:造血细胞对肿瘤及其转移的浸润可以对肿瘤的生长,浸润和患者预后产生正面和负面的影响。这些不同的结果与肿瘤异质性和浸润肿瘤性病变的白细胞多样性有关。组织细胞(巨噬细胞和树突状细胞(DC))浸润的肿瘤与不良的临床预后相关,尽管部分DC浸润与预后的改善相关。肿瘤和转移瘤的T细胞浸润是阳性结果的替代指标,尽管子集分析表明并非所有浸润的T细胞都具有这种潜力。总体而言,CD8(+)T细胞的肿瘤浸润与阳性结果相关,而CD4(+)细胞浸润的频率可能是阴性预测因子。除了巨噬细胞和T细胞对肿瘤的浸润外,最近的研究表明,髓样抑制细胞(MDSC)也浸润肿瘤,抑制T细胞和DC的数量和功能,并促进肿瘤的生长,血管生成和转移。总之,肿瘤的造血细胞浸润可以调节肿瘤的进展并提供有用的诊断替代。此外,专注于通过细胞,基因和分子免疫疗法控制细胞浸润的策略有可能为辅助治疗提供新的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号